80 likes | 233 Views
In Europe, growth in the aging population is boosting the biological drugs market. According to a UN report, 23.2% of the total German population in 2000 was elderly people and the number is expected to reach 33.2% in 2025. Aging leads to certain disorders such as age-related macular degeneration and glaucoma. These age-related disorders require effective biological drugs for treatment.
E N D
Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020
Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020 • Biological drugs are typically derived from living cells and are used in treatment of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs have more complex structure than conventional drugs. These are highly sensitive and more difficult to characterize and produce. A biological drug typically has around 250 in-process tests during manufacturing compared to about 50 tests for a conventional drug. • The global market of biological drugs is categorized based on therapeutic protein, mAb and vaccines. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.
Global Study on Biological Drugs Market • In terms of geography, North America has the largest market share followed by Europe and Asia in the global biological drugs market. Increased usage of biological drugs for the treatment of diseases, such as cancer, diabetes and other chronic diseases, are supporting the growth of the biological drugs market in the North American region. For instance, in 2012, the American College of Rheumatology, an organization that advances rheumatology through education and research, recommended biologic agents and disease modifying antirheumatic drugs for the treatment of rheumatoid arthritis. • In Europe, growth in the aging population is boosting the biological drugs market. According to a UN report, 23.2% of the total German population in 2000 was elderly people and the number is expected to reach 33.2% in 2025. Aging leads to certain disorders such as age-related macular degeneration and glaucoma. These age-related disorders require effective biological drugs for treatment.
Read Complete Report on Global Study on Biological Drugs Market • However, low manufacturing cost in Asia is attracting many biological manufactures to invest in Asian countries, supporting the growth of the biological drugs market. For instance, Lonza, a Swiss biotechnology company, invested about USD 350 million in Singapore and India, in order to encourage biological activities. • Globally, the biological drugs market is growing due to the increasing prevalence of chronic diseases and increasing global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical science holds immense potential for the growth of the biological drugs market. In addition, anti-Vascular Endothelial Growth Factor (VEGF) therapy and Genetically Modified Organisms (GMOs) are gaining importance in the biological drugs market.
Global Study on Biological Drugs Market • However, high cost of biological drugs and patent expiry of blockbuster drugs impede growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of biological drugs market. • The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the report. • Some of the major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. • These key market players have been profiled based on attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.
TOC Table of Content Chapter 1 Preface 11 1.1 Report Description 11 1.2 Report Methodology 12 1.3 Assumptions 12 Chapter 2 Market Synopsis 13 Chapter 3 Porter Five Forces Analysis 14 3.1 Bargaining power of suppliers 14 3.2 Bargaining power of buyers 15 3.3 Threat of new entrants 15 3.4 Threat of substitutes 15 3.5 Intensity of rivalry 15
TOC • Chapter 4 Industry Overview 17 • 4.1 Market Definition 17 • 4.2 Market Drivers 18 • 4.2.1 Increasing prevalence of chronic diseases enhance the market growth 18 • 4.2.2 Globally geriatric population increases the demand of biological drugs 19 • 4.2.3 Various government associations are promoting usage of biological drugs 20 • 4.3 Impact analysis of Market Drivers 21 • 4.4 Market Restraints 21 • 4.4.1 High cost of biological drugs impedes market growth 21 • 4.4.2 Patent expiration of various blockbuster biological drugs 22 • 4.4.3 Risk of adverse effects associated with biological injectable medicines 22 • 4.5 Impact analysis of Market Restraints 23 • 4.6 Opportunities 24 • 4.6.1 Advancement in biomedical science promises to boost the development of new biological products 24 • 4.7 Market Trends 24 • 4.7.1 VEGF therapy is gaining popularity in biopharmaceutical industry 24 • 4.7.2 GMOs are gaining importance in biological drugs market 25 • Chapter 5 Global Market Size And Forecast 26
Contact Us Addie Thomes 305 Broadway, 7th Floor, New York City, NY 10007, United States. Phone: +1-646-568-7751 USA/Canada Toll Free Number. 1-800-961-0353 E-mail:Sales@persistencemarketresearch.com Web : http://www.persistencemarketresearch.com